Recent Advances in Hidradenitis Suppurativa Treatment
Researchers and clinicians are making significant strides in understanding and treating Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition. This article highlights the latest studies, treatments, and insights that are paving the way for improved patient care. Here are some of the most noteworthy developments:
Orismilast’s Dose-Dependent Tolerability
A recent Phase 2a study on oral orismilast has shown promising results for HS patients. Investigators found the treatment to be dose-dependent in terms of tolerability. Moreover, the findings suggest that orismilast could contribute to meaningful clinical improvements in HS treatment. Read more here.
Lutikizumab Advances to Phase 3
Lutikizumab has demonstrated positive results in a Phase 2 trial for HS, with higher response rates observed among treated patients. Based on these outcomes, the drug has progressed to Phase 3 clinical trials. Discover the details.
Secukinumab Eclipses Other Treatments
Secukinumab has emerged as a leading treatment for HS, based on market research conducted by Spherix Global Insights. This survey involved more than 100 US dermatologists and provided valuable insights into the evolving landscape of HS treatment. Explore the market study.
Intravenous Ertapenem Therapy
Researchers suggest that IV antibiotics should not replace immunomodulator therapies, but rather play a complementary role in managing HS. This strategy can help reduce the burden of chronic symptoms for HS patients. Learn more about IV therapy.
Hippo Pathway and Fibrosis
Studies have implicated the Hippo pathway in HS development, particularly in extensive fibrosis. Researchers have discovered that inhibiting this pathway can modulate profibrotic responses in fibroblasts, offering potential new avenues for treatment. Read expert insights.
Uncertain Dietary Links
While some dietary elements like vitamin D and vitamin B12 have been studied in relation to HS, the connections are still inconclusive. More research is needed to determine the role of diet in HS severity. Find out more.
HSE: Clinical Care Tips
Dr. Ashley Nicole Elsensohn presented clinical pearls for HS excision at the Annual Meeting of the American Academy of Dermatology (AAD). These tips aim to improve excision care for the millions of patients affected by HS. Explore clinical tips.
Late-Breaking Data on Lutikizumab
Dr. Alexandra Kimball reviewed late-breaking data on lutikizumab for HS at the AAD Annual Meeting. These results show promise for treating difficult-to-treat HS cases where TNF therapy has failed. Read the latest findings.
Bimekizumab: FDA Approval Anticipated
Positive results from phase 3 trials (BE HEARD I and BE HEARD II) have led to the FDA accepting supplemental biologics license applications for bimekizumab to treat HS. If approved, it will be the first inhibitor of IL-17A and IL-17F for HS in Europe. Get the expert perspective.
Surgical Procedures for HS
MD Maria Aleshin shared surgical options suitable for HS that can be performed in an office setting. This information is valuable for dermatologists looking to improve their management of HS patients. Find surgical procedures.
Maternal HS and Childhood Morbidity
Research has linked maternal HS to increased risk of childhood morbidity. A recent study presented at the AAD Annual Meeting and awarded second-place best poster underscored this relationship. Read the study findings.
Bimekizumab EU Approval
The European Commission has approved bimekizumab for treating moderate to severe HS based on phase 3 trial data. If approved in the US, it will offer a new treatment option for HS patients. Discover the EU approval.
HST in Transgender and Gender-Diverse Populations
Recent research explored HS in transgender and gender-diverse patients, finding that initiating gender-affirming hormone therapy with testosterone can worsen HS symptoms. Read about the findings.
Povorcitinib Development in China
Incyte and CMS are collaborating to develop povorcitinib, an inhibitor of Janus kinases (JAK). The drug is being evaluated for HS treatment among numerous conditions in China. Learn more about the development.
AI Chatbots for HS Support
A recent study assessed AI chatbots’ potential in providing accurate information to HS patients. This emerging technology could offer new tools for patients and dermatologists to manage HS. Discover more about AI support.
Dr. Jeff Stark’s Insights
Dr. Jeff Stark provided insights on the approval of bimekizumab for HS, highlighting the pivotal BE HEARD trials. These trials demonstrated efficacy, showing meaningful improvements in HS patients over placebo. Read Dr. Stark’s thoughts.
Advances in HS Treatment
In an interview, Dr. Christopher Sayed discussed recent advances in HS treatment. These advances include phase 3 trials of bimekizumab and ongoing research on immunomodulators and biologics. Explore treatment advances.
HS Advocacy Journey
Dena Antowan shared her journey as a pre-med student living with HS, balancing school life while advocating for empathetic dermatologic care. Her story inspires and informs both patients and healthcare providers. Read Dena’s journey.
Stay informed about the latest in dermatology and Hidradenitis Suppurativa research by subscribing to our monthly eNewsletters. Don’t miss a thing—sign up today to receive the free print issue and supplements each month. Join our community and explore more on Dermatology Times.
